Pancreatic Cancer Research

Clinical trialPhase 4Withdrawn

Pasireotide Treatment for Neuroendocrine Tumor

Pasireotide Treatment for Insulin Producing Pancreatic Neuro-endocrine Tumor

Outcome
Stopped earlySubject passed away prior to enrollment (Enrollment)
Phase
Phase 4
Status
Withdrawn
Study type
Interventional
Planned start
April 2016
Planned end
June 2016
Enrollment
0 participants
Sites
0
Primary outcomes
Hypoglycemia
Sponsor type
Academic / other
Results posted
No
Last update
4 March 2022

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

Pasireotide binds to somatostatin receptors sst2 and sst5, which can lead to significant hyperglycemia. The investigators would like to administer pasireotide as a treatment for refractory hypoglycemia in the setting of metastatic insulin-producing pancreatic neuro-endocrine tumor.